Pulmatrix, Inc. (PULM) Fair Value 2026

PULM · Pharmaceutical Preparations ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

6.1 /10

32 fundamental signals · 9 models active

Value Trap Risk

SAFE (24/100)

Quick Summary — As of 2026-07-15, Pulmatrix, Inc. (PULM) trades at $1.57, approximately 68% above CirclFi’s Bayesian DCF fair value of $0.93. QOC: 6.1/10. Value Trap Risk: 24/100 (SAFE). 9/13 models active.

Key Facts

Ticker
PULM
Price
$1.57
Quality Score
6.1/10
Value Trap Risk
24/100
Models Active
9/13
Last Updated
Strength: Dynamic NAV suggests +205.6% upside with 43% confidence
Risk: Limited model coverage (9/13) may reduce confidence

Is Pulmatrix, Inc. (PULM) Undervalued or Overvalued in 2026?

According to CirclFi’s 9-model valuation engine, Pulmatrix, Inc. (PULM) appears undervalued as of : the median of 9 independent fair value estimates is $3.41, 117.4% above the current price of $1.57. Estimates range from $0.04 to $5.70. PULM scores 6.1/10 on fundamental quality and 24/100 on value-trap risk.

This verdict compares price to intrinsic value only — it is not a buy or sell rating. For the decision case (bull vs bear arguments, risk factors, peers), read Should You Buy Pulmatrix, Inc. Stock in 2026? →

Valuation Matrix

9 Intrinsic Value Models vs. Current Price ($1.57)

Core Models (Unlocked)
Model Fair Value Upside
Bayesian DCF
Low Conviction
$0.93 -40.5%
CUCE Ensemble
Low Conviction
$3.41 +117.4%
First Chicago
Low Conviction
$3.84 +144.7%
Dynamic NAV
Medium Conviction
$4.80 +205.6%

Unlock the Full Matrix

Access 5 additional models including ML-RIV, PWERM, and more.

$1.30 / day

Billed monthly ($39/mo) or annually ($299/yr)

Unlock All 9 Models →

Cancel anytime · No contracts · Instant access

What Is Pulmatrix, Inc. (PULM) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, our multi-model framework produces a cautiously optimistic read on Pulmatrix, Inc. at $1.57. With an estimated intrinsic value of $3.05 and 6 of 9 models pointing higher, the average implied return is +94.5%. The most optimistic model, Regime Cross, places fair value at $5.70 (+262.9%), while ML-RIV — the most conservative — estimates $0.04 (-97.4%). This +360.4% gap reflects genuine analytical uncertainty about Pulmatrix, Inc.'s intrinsic worth.

What Do the Models Say About PULM?

9 of 13 models are currently active for PULM. Of these, 7 models suggest upside while 2 models suggest overvaluation. The Bayesian DCF estimates PULM's intrinsic value at $0.93, implying -40.5% downside from the current price. See which stocks rank higher →

How Does PULM Rank in Pharmaceutical Preparations?

Among 431 Pharmaceutical Preparations stocks, PULM ranks #118 by Quality of Company score. CirclFi's QOC score of 6.1/10 evaluates 32 fundamental signals. A score of 6.1 indicates above-average quality.

See all Most Undervalued Pharmaceutical Preparations Stocks →

The Pharmaceutical Preparations sector introduces analytical considerations specific to pharmaceutical industry businesses. For Pulmatrix, Inc., metrics like FDA approval probability provide important context that general-purpose valuation models may underweight.

Is PULM a Value Trap?

CirclFi's Value Trap algorithm assigns PULM a score of 24/100 (SAFE). This indicates minimal risk. Fundamentals are healthy. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

9 of 13 models are active for Pulmatrix, Inc.. Moderate coverage provides meaningful perspective. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi Deep Alpha Valuation Engine, Pulmatrix, Inc. scores 6.1 out of 10 on our 32-signal quality assessment, a solid rating that maintains reasonable quality metrics with some areas for improvement. The QOC score synthesizes profitability margins, revenue growth reliability, debt management, and capital allocation into a single metric designed to separate durable businesses from statistically cheap ones.

The gap between the most bullish and bearish model spans +360.4% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every PULM valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across PULM's 9 active models, average confidence is 22%. Lower confidence may reflect limited history or high volatility.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Pulmatrix, Inc. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Pharmaceutical Preparations Stocks Should You Also Analyze?

8 related Pharmaceutical Preparations stocks with 13-model coverage

Read investment analysis: AZN · CPRX · HRMY · NVO · SIGA

See all Pharmaceutical Preparations stocks ranked →

Frequently Asked Questions About Pulmatrix, Inc.

What is Pulmatrix, Inc.'s intrinsic value in 2026?

Based on CirclFi's 13-model analysis, Pulmatrix, Inc. (PULM) has multiple fair value estimates. The Bayesian DCF model runs 10,000 Monte Carlo simulations with jump-diffusion to estimate intrinsic value at $0.93. The Quality of Company score is 6.1/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is PULM overvalued or undervalued right now?

At $1.57, 7 of 9 active models suggest PULM may be undervalued, while 2 indicate potential overvaluation. The median of all 9 fair value estimates is $3.41, 117.4% above the current price of $1.57 — a consensus view that PULM is undervalued. The assessment depends on which methodology best fits Pulmatrix, Inc.'s business model in Pharmaceutical Preparations.

What does a Quality of Company score of 6.1 mean for PULM?

Pulmatrix, Inc.'s QOC of 6.1/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores between 5-7 reflect moderate fundamentals with areas for improvement.

How many valuation models does CirclFi run on PULM?

CirclFi analyzes PULM with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 9 of 13 are active for this stock. Read the full methodology →

Is PULM a value trap in 2026?

Pulmatrix, Inc.'s Value Trap score is 24/100 (SAFE). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap. Browse stocks by value-trap risk →

Cite this analysis — “According to CirclFi’s 9-model valuation engine, Pulmatrix, Inc. (PULM) has a median fair value of $3.41 — 117.4% above the current price of $1.57 — as of 2026-07-15.” Source: circlfi.com/stock/PULM/ · Methodology

You’ve done the research. Don’t stop at half the picture.

Stop collecting opinions. Let 9 mathematical frameworks give you clarity on PULM.

Unlock All 9 Fair Values — $39/mo

Cancel anytime · Less than a cup of coffee · Instant access